DDInter923 DDInter1676
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Infliximab may lead to a major life threatening interaction when taken with Aldesleukin